Dispatch Bio has dosed the first participant in a Phase I clinical trial aimed at evaluating the efficacy and safety of its new investigational immunotherapy, DISP-10, in advanced gastrointestinal (GI) cancers.
The first-in-human trial targets adults with advanced GI cancers, including colorectal, gastric, oesophageal, and gastroesophageal adenocarcinomas.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The participant has completed the dose-limiting toxicity assessment according to the study’s protocol.
This ongoing multi-centre, open-label study also focuses on examining the tolerability, and preliminary efficacy of DISP-10.
DISP-10 comprises two key components. The first, DV-10, is a virus engineered to deliver a modified B cell maturation antigen, along with Interleukin-18 (IL-18) and C-X-C motif chemokine ligand 9 (CXCL9), aimed at altering tumour cells and enhancing T cell activity.
The second component is Bristol Myers Squibb’s ide-cel, a chimeric antigen receptor (CAR) T cell therapy, which received approval in the US, though not for solid tumours.
DISP-10 has received fast track designation from the US Food and Drug Administration (FDA) for the treatment of advanced gastrointestinal cancers.
Colorectal cancer is the primary cause of death in individuals aged under 50 years. Dispatch Bio is seeking to address these challenges through DISP-10, offering a new approach to cancer immunotherapy.
Dispatch Bio chief medical officer Mauro Avanzi said: “Initiating this trial represents a meaningful step forward for patients with advanced GI cancers, reinforced by the FDA’s fast track designation for DISP-10.
“We look forward to advancing this study as we work to overcome the longstanding limitations of treating solid tumours with immunotherapy, including lack of a safe and homogeneously expressed target antigen, a narrow therapeutic window, and an inhibitory tumour microenvironment.”
